GleamWall
中文EN

CPMD CANNAPHARMARX, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1081938 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-30.8%
TTM net income YoY-25.6%
TTM EPS YoY50.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-114.1%
Operating margin-210.8%
Net margin-779.2%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-97.3%
ROIC (approx.)—
Asset turnover0.12x

Leverage & solvency

Liabilities / assets514.2%
Debt / equity—
Current ratio0.05x
Interest coverage-1.70x

Cash quality & payout

Operating cash flow / net income-0.06x
Accruals ratio-102.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.36M$820,137
Cost of revenue$3.45M$3.76M
Gross profit-$2.08M-$2.93M
SG&A expense$489,641$145,713
Operating income-$3.35M-$3.63M
Interest expense$1.96M$2.26M
Income tax$0$0
Net income-$11.13M-$9.91M
EBITDA—-$3.63M
EPS (diluted)-0.02-0.02
Weighted avg. shares (diluted)662.50M625.28M
Balance sheet
Cash & equivalents$1,804$2,156
Receivables$164,430$1,747
Inventory$1.12M$996,250
Current assets$1.31M$1.02M
PP&E, net$127,029$137,237
Total assets$7.02M$10.84M
Current liabilities$31.59M$25.75M
Total liabilities$37.17M$30.65M
Shareholders' equity-$30.15M-$19.81M
Shares outstanding662.50M662.50M
Cash flow statement
Operating cash flow-$789,102-$1.70M
Capital expenditure$5,519$0
Free cash flow-$794,621-$1.70M
Investing cash flow$794,269$1.70M
Financing cash flow-$5,519$0
Depreciation & amortization—$0

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.